These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17786724)

  • 1. Patients with bisphosphonate-associated osteonecrosis of the jaw have unmodified levels of soluble vascular endothelial growth factor receptor 1.
    Alonci A; Allegra A; Bellomo G; Quartarone E; Oteri G; Nastro E; Cicciù D; De Ponte FS; Musolino C
    Leuk Lymphoma; 2007 Sep; 48(9):1852-4. PubMed ID: 17786724
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration.
    Oteri G; Allegra A; Bellomo G; Alonci A; Nastro E; Penna G; Catalfamo L; Cicciù D; De Ponte FS; Musolino C
    Cytokine; 2008 Aug; 43(2):103-4. PubMed ID: 18585926
    [No Abstract]   [Full Text] [Related]  

  • 3. Bisphosphonate-induced osteonecrosis of the jaw: long-term outcomes.
    Katz J; George T; Sandow P; Machado M; Dickerson L; Moreb JS
    J Support Oncol; 2009; 7(1):9-10. PubMed ID: 19278171
    [No Abstract]   [Full Text] [Related]  

  • 4. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series.
    Fedele S; Porter SR; D'Aiuto F; Aljohani S; Vescovi P; Manfredi M; Arduino PG; Broccoletti R; Musciotto A; Di Fede O; Lazarovici TS; Campisi G; Yarom N
    Am J Med; 2010 Nov; 123(11):1060-4. PubMed ID: 20851366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Osteonecrosis of the jaw in the course of multiple myeloma treatment and bisphosphonate administration].
    Adam Z; Kozumpliková M; Pour L; Machálka M
    Vnitr Lek; 2006 Feb; 52(2):176-80. PubMed ID: 16623282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Avascular jaw osteonecrosis associated with bisphophonate therapy].
    Broglia C; Merlati G; Valentino F; Benatti C; Gobbi P; Ascari E
    Recenti Prog Med; 2006 Mar; 97(3):140-4. PubMed ID: 16700419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review].
    Li LH; Wu XB; Chen WM; Chen JX; Wu Y; Chen SL
    Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2986-7. PubMed ID: 19080077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survey of members of myeloma UK on biphosphonates-associated jaw osteonecrosis.
    Barker K; Lowe D; Olujohungbe A; Low E; Rogers SN
    Br J Haematol; 2007 Nov; 139(4):626-8. PubMed ID: 17922879
    [No Abstract]   [Full Text] [Related]  

  • 9. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.
    Kraj M; Pogłód R; Maj S; Owczarska K
    Acta Pol Pharm; 2006; 63(5):450-2. PubMed ID: 17357613
    [No Abstract]   [Full Text] [Related]  

  • 10. [Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis].
    Neumann B; Gregersen H
    Ugeskr Laeger; 2006 May; 168(21):2078-9. PubMed ID: 16768928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate complications including osteonecrosis of the jaw.
    Mehrotra B; Ruggiero S
    Hematology Am Soc Hematol Educ Program; 2006; ():356-60, 515. PubMed ID: 17124083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws.
    Allegra A; Alonci A; Penna G; Granata A; Nastro Siniscalchi E; Oteri G; Loddo S; Teti D; Cicciù D; De Ponte FS; Musolino C
    Acta Haematol; 2010; 124(2):79-85. PubMed ID: 20639624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients.
    Petrucci MT; Gallucci C; Agrillo A; Mustazza MC; Foà R
    Haematologica; 2007 Sep; 92(9):1289-90. PubMed ID: 17768133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dilemma of jaw osteonecrosis in patients with multiple myeloma.
    Gertz MA; Koka S
    Leuk Lymphoma; 2008 Nov; 49(11):2037-9. PubMed ID: 19021045
    [No Abstract]   [Full Text] [Related]  

  • 15. [The complications during the therapy for multiple myeloma].
    Spicka I
    Vnitr Lek; 2006 Feb; 52(2):115. PubMed ID: 16623271
    [No Abstract]   [Full Text] [Related]  

  • 16. Multiple myeloma.
    Altundag K; Altundag O; Gundeslioglu O
    N Engl J Med; 2005 Feb; 352(8):840-1; author reply 840-1. PubMed ID: 15728824
    [No Abstract]   [Full Text] [Related]  

  • 17. Osteonecrosis of the jaw and bisphosphonates.
    Durie BG; Katz M; Crowley J
    N Engl J Med; 2005 Jul; 353(1):99-102; discussion 99-102. PubMed ID: 16000365
    [No Abstract]   [Full Text] [Related]  

  • 18. Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.
    Delibasi T; Altundag K; Kanlioglu Y
    J Oral Maxillofac Surg; 2006 Jun; 64(6):995-6. PubMed ID: 16713825
    [No Abstract]   [Full Text] [Related]  

  • 19. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.
    Ruggiero SL; Fantasia J; Carlson E
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct; 102(4):433-41. PubMed ID: 16997108
    [No Abstract]   [Full Text] [Related]  

  • 20. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment.
    Dickinson M; Prince HM; Kirsa S; Zannettino A; Gibbs SD; Mileshkin L; O'Grady J; Seymour JF; Szer J; Horvath N; Joshua DE
    Intern Med J; 2009 May; 39(5):304-16. PubMed ID: 19220531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.